Updated Aug 13 at 4:03pm ET.
Follow DexCom to never miss an important update.
Argus Research raised its price target for the company to $96. This follows a strong quarterly report where the business showed it is successfully expanding its reach into international markets.
While the stock has been volatile recently, analysts are increasingly focused on the company's ability to grow beyond its traditional base of insulin users. This higher target suggests confidence that the business can maintain its premium position even as it moves into the broader health wearable market.
Source: Argus Research
Canaccord Genuity increased its price target to $90 following the company's latest financial results. The firm is keeping a positive rating on the stock as the business continues to grow its revenue and expand its user base globally.
Source: Canaccord Genuity
The company reported quarterly revenue of about 1.31 billion dollars, which was higher than the 1.29 billion dollars analysts expected. Profit also came in ahead of targets. Sales in the U.S. grew 11 percent, while international sales jumped 19 percent as more people outside the country adopt its glucose monitoring sensors.
Management raised its sales forecast for the full year, signaling that demand remains strong. This is a positive sign for the business as it tries to move beyond its core market of insulin users and into broader health tracking. The company also showed better efficiency, with operating income margins rising significantly compared to last year. This suggests that as the business scales, it is becoming more profitable on each dollar of sales.
See the full quarter, and how our tracked metrics did
Source: 8-K filing
Kaskela Law Firm announced it is investigating the company on behalf of long-term investors. The investigation relates to a securities fraud complaint involving the period between January 2024 and September 2025. These types of investigations and lawsuits are common for large public companies, especially after periods of stock price volatility. Unless the case gains significant legal traction or leads to a large settlement, it is unlikely to change the long-term outlook for the business.
Source: Business Wire
The U.S. Food and Drug Administration (FDA) selected the company as the first participant in its TEMPO pilot program. This initiative aims to see how digital health technologies, like the company's glucose sensors, can provide real-world evidence to improve how chronic diseases are managed.
Being the first participant gives the company a seat at the table as the FDA develops new ways to regulate and evaluate digital health tools. This could help the company get its future products through the approval process more efficiently and reinforces its position as a leader in medical sensor technology.
Source: Business Wire
Analysts issued a flurry of price target increases following the company's strong second-quarter earnings report. Most analysts, 42 of 52, rate the stock a buy, though the average target of $90 is slightly below the current price.
The company has a very consistent track record, beating analyst profit targets in six of the last eight quarters. This suggests management is skilled at setting reachable goals and then clearing them.
| Expectation | |
|---|---|
| EPS | $0.66 |
| Revenue | $1.33B |
